Idexx Laboratories is a global leader in veterinary diagnostics, providing a wide range of innovative products and services that enhance animal health and well-being
The company develops and manufactures diagnostic tests and equipment for companion animals, livestock, and poultry, helping veterinarians and livestock producers make informed health decisions. Additionally, Idexx offers various software solutions for practice management and laboratory information, along with water testing services to ensure public safety and environmental protection. With a commitment to advancing veterinary medicine and improving animal care, Idexx plays a crucial role in the healthcare ecosystem for animals and the people who care for them.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top S&P500 gainers and losers in today's session.
Wall Street bounced back after President Donald Trump and Mexican President Claudia Sheinbaum agreed to a one-month suspension of tariffs following Mexico's pledge to bolster its military presence at the northern borde
Idexx Laboratories posted strong Q4 earnings, beating estimates with 10% EPS growth. 2025 guidance reflects up to 7% revenue growth and $1.5 billion in buybacks.
Katy Huberty, the Global Head of Research at Morgan Stanley, has spotlighted 20 stocks from companies that are likely to see significant benefits from the adoption of Artificial Intelligence (AI).
IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 fourth quarter and full year financial results for Monday, February 3, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.
Synopsys, Inc. Named Outstanding Leader, Nell Triplett of Juniper Networks Awarded Outstanding Executive, and IDEXX Laboratories, Inc. Recognized as Breakthrough Corporate Leader
IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, today announced that the Company’s Board of Directors authorized an increase in its ongoing share repurchase program, authorizing the repurchase of up to five million additional shares of the Company’s common stock. Repurchases may be made at management’s discretion from time to time in the open market (including through Rule 10b5-1 plans) or in negotiated transactions. These shares are in addition to the 1.3 million shares remaining under the Company’s ongoing share repurchase program as of December 3, 2024, pursuant to previous Board authorizations. The share repurchase program has no specified expiration date and may be suspended or discontinued at any time.
IDEXX Laboratories, Inc. (NASDAQIDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon has decided to retire from IDEXX effective June 1, 2025. Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group (“CAG”) Finance, will succeed Mr. McKeon as IDEXX’s Executive Vice President, Chief Financial Officer and Treasurer, effective March 1, 2025. Mr. McKeon will serve as EVP and Special Advisor to the Company from March 1, 2025 until his retirement from IDEXX on June 1, 2025, to help ensure a smooth and seamless transition.
Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today.
